CPRX News and Press, Catalyst Pharmaceuticals Inc. From 08/11/20

Fennec Pharmaceuticals (NASDAQ: FENC )   -31%  on FDA rejection of Pedmark application. More news on: Fennec Pharmaceuticals Inc., Mesoblast Limited, Genesis Healthcare, Inc., Stocks on the move, , Read more ...

CORAL GABLES, Fla., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologic...

Catalyst Pharmaceuticals (NASDAQ: CPRX ) : Q2 GAAP EPS of $0.09 in-line. Revenue of $29.6M (+2.6% Y/Y) beats by $0.12M . Research and development expenses $4.3M vs. $4.6M in 2Q19. Shares -18% . Press Release More news on: Catalyst Pharmaceuticals, Inc., Earnings news and comme...

- Firdapse ® Second Quarter Net Revenues of $29.6 Million - Health Canada Approves Marketing Authorization for Firdapse ® for Treating LEMS Patients - MuSK-MG Phase 3 Trial did not Achieve Statistical Significance for Primary or Secondary Endpoints - Company to Hos...

It's become conventional wisdom on Wall Street that the Robinhood trading platform is a playground for young, inexperienced day traders chasing the quick buck -- so-called "dumb money" following the latest trend. Well, maybe experienced investors shouldn't be so quick to judge. A report by Gol...

Introduction To keep myself sharp and my skills honed, I routinely go to my library of investment books and re-read classics that have had an impact on me. This week, I did a complete re-read of Joel Greenblatt's classic "The Little Book That Beats The Market." For any of you that are not ...

CORAL GABLES, Fla., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologic...

Immunic announced positive top line data for IMU-838 Immunic Inc. ( IMUX ) announced top line data from Phase EMPhASIS trial of lead drug candidate, IMU-838, aimed at patients with relapsing-remitting multiple sclerosis or RRMS. The company reported that the trial achieved all its primar...

CORAL GABLES, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologic...

CORAL GABLES, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologic...